Publications – Dr. Ryan Million, PhD

Shani K and Million RP. The Role of Value in Drug Pricing. Contract Pharma. 2016 Oct. http://www.contractpharma.com/issues/2016-10-01/view_features/the-role-of-value-in-drug-pricing/

Million RP. Drug Pricing: Oncology in the United States. Trinity Partners white paper. 2016 Jun.

Upda N and Million RP. Monoclonal antibody biosimilars. Nature Rev Drug Disc. 2016 Jan 15(1): 13-4.

Chizkov RR and Million RP. Trends in breakthrough therapy designation. Nature Rev Drug Disc. 2015 Sep 14(9): 597-8.

Hernandez RK, Adhia A, Wade SW, O’Connor E, Arellano J, Francis K, Alvrtsyan H, Million RP and Liede A. Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States. Clinical Epidemiology. 2015 7: 335-45.

Bartlett HS and Million RP. Targeting the IL-17-T­H17 pathway. Nature Rev Drug Disc. 2015 Jan 14(1): 11-2.

O’Connor E, Scaife J and Million RP. Challenges to the Specialty Business Model. Pharmaceutical Executive. 2014 June 34(6): 52-3.

DeWoskin VA and Million RP. The Epigenetics Pipeline. Nature Rev Drug Disc. 2013 Sep 12(9): 661-2.

Scaife J, Kuti E, Acampa L, Million RP, Miyasato G, Wang Z, Sander S, Sanchez H, Kokkotos F. Prevalence of Hepatic Outcomes Among Medicare Beneficiaries Diagnosed with Chronic Hepatitis C Virus. Value in Health 2013 16(3): A82.

Scaife J, Kuti E, Acampa L, Million RP, Miyasato G, Wang Z, Sander S, Sanchez H, Kokkotos F. Characteristics of Medicare Beneficiaries with Chronic Hepatitis C Virus. Value in Health 2013 16(3): A82.

Scaife J, Kuti E, Acampa L, Million RP, Miyasato G, Wang Z, Sander S, Sanchez H, Kokkotos F. Prevalence of Hepatic Outcomes Among Commercially-Insured Patients Diagnosed with Chronic Hepatitis C Virus. Value in Health 2013 16(3): A82.

Scaife J, Kuti E, Acampa L, Million RP, Miyasato G, Wang Z, Sander S, Sanchez H, Kokkotos F.Prevalence of Chronic Hepatitis C Virus and Commonly-associated Comorbidities within a Large US Commercially-Insured Population. Value in Health 2013 16(3): A82.

Scaife J, Kuti E, Acampa L, Alvrtsyan H, Million RP, Miyasato G, Wang Z, Sander S, Sanchez H, Kokkotos F. Uninsured Chronic Hepatitis C Patients and Their Cost Implications Under the Affordable Care Act. Value in Health 2013 16(3): A98.

Zolot RS, Basu S and Million RP. Antibody-drug conjugates. Nature Rev Drug Disc. 2013 Apr 12(4): 259-60.

Chiang A and Million RP. Personalized medicine in oncology: next generation. Nature Rev Drug Disc. 2011 Dec 10(12): 895-6.

Clark MJ and Million RP. Allergic rhinitis: market evolution. Nature Rev Drug Disc. 2009 Apr 8(4): 271-2.

Million RP. Therapeutic area crossroads: anti-angiogenesis. Nature Rev Drug Disc. 2008 Feb; 7(2): 115-6.

Herrick TM and Million RP. Tapping the Potential of Fixed-dose Combinations. Nature Rev Drug Disc. 2007 Jul; 6(7): 513-4.

Million RP. Impact of genetic diagnostics on drug development strategy. Nature Rev Drug Disc. 2006 Jun; 5(6):459-62.

 Million RP, Harakawa N, Roumiantsev S, Varticovski L, Van Etten RA. A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol. 2004 Jun;24(11):4685-95.

Million RP, Aster J, Gilliland DG and Van Etten RA. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood. 2002 Jun 15;99(12):4568-77.

Million RP and Van Etten RA. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood. 2000 Jul 15;96(2):664-70.

Li S, Ilaria RL Jr., Million RP, Daley GQ and Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999 May 3;189(9):1399-412.

Prior  TEAM  Next